Final Programme - iuphar

FC13 Maximising benefits and minimizing harms from
drugs
Tue 317 The expression of 14-3-3 subtypes in uterine leiomyoma
Ouping Huang, (PR China), SF Fang, L Wang, D Yin, B Yi, L Tang, M He
Tue 318 Effect of losartan on metabolism of arachidonic acid in human liver microsomes
Nobuo Inotsume, (Japan), T Toda, K Sakamoto, S Takeuchi, T Hayakawa, B Ask, E Eliasson, A Rane
Tue 319 Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in
Sahiwal cattle
Zahid Iqbal, (Pakistan), A Basit, I Javed, IU Jan, UA Khan
Tue 320 Inhibitory effects of OTC-drugs on cytochrome P450 in human liver microsome
Mariko Iwase, (Japan), Y Nishimura, N Kurata, Y Saito, N Uchida, H Yasuhara
Tue 321 Amoxicillin pharmacokinetics in patients with aspiration pneumonia as a complication of overdosage
with psychotropic drugs: a pilot study
Dusan Jandric, (Republic of Serbia), V Dragojevic-Simic, B Ciric, D Jovanovic, V Kilibarda, S Vucinic,
S Dobric
Tue 322 Total and free clearance of R- and S-warfarin in elderly people
Berit P Jensen, (New Zealand), P Chin, RR Roberts, J Maddison, EJ Begg
Tue 323 CYP2C9*3 and *13 alleles significantly affected the pharmacokinetics of meloxicam in healthy subjects
Kyeong-Joo Jeon, (Republic Of South Korea), C-I Choi, J-W Bae, M-J Kim, C-G Jang, S-Y Lee
Tue 324 The role of CYP2C9 genetic variants in the disposition of glipizide in healthy subjects
Kyeong-Joo Jeon, (Republic Of South Korea), C-I Choi, J-W Bae, M-J Kim, C-G Jang, S-Y Lee
Tue 325 Pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after multiple-dose oral
administration of L-carnitine solution in healthy subjects
Fanbo Jing, (PR China), H Qu, Z Sui, Y Cao, Z Han, L Zhu, C Wang
Tue 326 Potentially inappropriate drug prescription in hospitalized geriatric patients
Marcela Jirón, (Chile), P Jara, L Escobar, S Orellana, I Huala, L Arriagada, MD Castillo, VH Carrasco
Tue 327 Cockcroft-Gault and MDRD in estimating renal function in older heart failure patients – implications for
prescribing of predominantly renally cleared medications
Sally Johns, (Australia), J Maddison, S Shakib
Tue 328 Erythropoietin use in cancer-related anemia in Croatia
Danica Juricic, (Croatia), S Badzek, L Bielen, V Erdeljic, K Makar-Ausperger, M Radacic-Aumiler,
R Likic, I Francetic
Tue 329 Prediction of non-compliance with antibiotic therapy in ambulatory patients
Kristina Kandrotaite, (Lithuania), V Neverauskas, M Jievaltas, V Saferis, V Briedis, R Maciulaitis
Tue 330 Gemfibrozil markedly increases the plasma concentrations of montelukast: A previously unrecognized
role for CYP2C8 in the metabolism of montelukast
Tiina Karonen, (Finland), J Laitila, M Niemi, P Neuvonen, J Backman
Tue 331 CYP2D6 genetic polymorphism has an impact on the pharmacokinetics of carvedilol in Korean subjects
Seul-Ki Keum, (South Korea), J-W Bae, C-G Jang, S-Y Lee
Tue 332 Gliclazide pharmacokinetics in relation to CYP2C19 genotype in healthy Koreans
Seul-Ki Keum, (South Korea), C-I Choi, J-W Bae, C-G Jang, S-Y Lee
224 Tuesday 20 July ■ 13:00 - 14:00 ■ Poster Area